SCHEMBL3208283

SCHEMBL3208283

FC(F)(F)c1cnc(CCl)c(Cl)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
KMT2A Q03164 3/20 0.54
ALDH1A1 P00352 4/20 0.50
HTT P42858 2/20 0.49
GAA P10253 1/20 0.49
MEN1 O00255 2/20 0.48
CYP1A2 P05177 2/20 0.48
CYP3A4 P08684 2/20 0.48
CYP2D6 P10635 2/20 0.48
CYP2C19 P33261 2/20 0.48
CYP2C9 P11712 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
RAB9A P51151 1/20 0.48
PLAU P00749 1/20 0.47
KDM4E B2RXH2 1/20 0.47
POLB P06746 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MAPT P10636 1/20 0.47
GLA P06280 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31255154 1.00 TDP1 (0.59) TDP1L3MBTL1KMT2AALDH1A1HTT
SCHEMBL28205018 0.89 TDP1 (0.61) TDP1L3MBTL1KMT2AALDH1A1HTT
SCHEMBL19584403 0.85 TDP1 (0.56) TDP1L3MBTL1KMT2AALDH1A1HTT
SCHEMBL31255260 0.83 TDP1 (0.58) TDP1L3MBTL1KMT2AALDH1A1HTT
SCHEMBL1722652 0.83 TDP1 (0.58) TDP1L3MBTL1KMT2AALDH1A1HTT
SCHEMBL30478413 0.83 TDP1 (0.58) TDP1L3MBTL1KMT2AALDH1A1HTT
SCHEMBL11982024 0.83 TDP1 (0.58) TDP1L3MBTL1KMT2AALDH1A1HTT
SCHEMBL2278694 0.83 TDP1 (0.58) TDP1L3MBTL1KMT2AALDH1A1HTT
SCHEMBL9290492 0.83 TDP1 (0.58) TDP1L3MBTL1KMT2AALDH1A1HTT
SCHEMBL635541 0.83 TDP1 (0.58) TDP1L3MBTL1KMT2AALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026099838-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF FLUOPYRAM BEST AGROLIFE LIMITED (IN) 2026-05-15 WO claimed
CN-118772049-B Preparation process of 3-chloro-2-aminoethyl-5-trifluoromethyl pyridine 山东滨农科技有限公司 2025-04-11 CN claimed
CN-118772049-A Preparation process of 3-chloro-2-aminoethyl-5-trifluoromethyl pyridine 山东滨农科技有限公司 2024-10-15 CN claimed
WO-2026099838-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF FLUOPYRAM BEST AGROLIFE LIMITED (IN) 2026-05-15 WO disclosed
EP-4638436-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2025-10-29 EP disclosed
US-12428397-B2 Factor XI activation inhibitors MERCK SHARP & DOHME LLC (US) 2025-09-30 US disclosed
CN-120441476-A Synthesis method of 2- (3-chloro-5- (trifluoromethyl) pyridin-2-yl) acetonitrile 天津均凯农业科技有限公司 2025-08-08 CN disclosed
EP-4149917-B1 FACTOR XI ACTIVATION INHIBITORS MERCK SHARP & DOHME LLC (US) 2025-07-30 EP disclosed
CN-118772049-B Preparation process of 3-chloro-2-aminoethyl-5-trifluoromethyl pyridine 山东滨农科技有限公司 2025-04-11 CN disclosed
CN-118772049-B Preparation process of 3-chloro-2-aminoethyl-5-trifluoromethyl pyridine 山东滨农科技有限公司 2025-04-11 CN disclosed
CN-118772049-A Preparation process of 3-chloro-2-aminoethyl-5-trifluoromethyl pyridine 山东滨农科技有限公司 2024-10-15 CN disclosed
US-20020025976-A1 Thiazole compounds and pharmaceutical compositions for inhibiting protein kinases and methods for their use AGOURON PHARMACEUTICALS, INC. 2002-02-28 US disclosed
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors ABBOTT LABORATORIES 2002-02-14 US disclosed
CN-1335847-A Sulfonamide compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO (JP) 2002-02-13 CN disclosed
CN-1335837-A Imidazole compounds and medicinal use thereof FUJISAWA PHARMACEUTICAL CO (JP) 2002-02-13 CN disclosed
WO-2001081316-A2 SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS ABBOTT LABORATORIES (US) 2001-11-01 WO disclosed
EP-1142879-A1 IMIDAZOLE COMPOUNDS AND MEDICINAL USE THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-10-10 EP disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed
WO-2001011965-A1 FUNGICIDES AVENTIS CROPSCIENCE GMBH (DE) 2001-02-22 WO disclosed
WO-2001012604-A1 FUNGICIDES AVENTIS CROPSCIENCE GMBH (DE) 2001-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020025976-A1 Thiazole compounds and pharmaceutical compositions for inhibiting protein kinases and methods for their use BRAF, CDK2, CHUK TDP1 891/4885L3MBTL1 4722/4885KMT2A 4434/4885
US-12428397-B2 Factor XI activation inhibitors F11, TFPI, F13B TDP1 2384/4885L3MBTL1 4627/4885KMT2A 3010/4885
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors FNTA, FNTB, SLC10A1 TDP1 1874/4885L3MBTL1 2965/4885KMT2A 3687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.